FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2111241903> ?p ?o ?g. }

• W2111241903 endingPage "1172" @default.
• W2111241903 startingPage "1164" @default.
• W2111241903 abstract "Abstract BACKGROUND Biomarkers may play an important role in identifying patients at risk for cancer therapy cardiotoxicity. Our objectives were to define the patterns of change in biomarkers with cancer therapy and their associations with cardiotoxicity. METHODS In a multicenter cohort of 78 breast cancer patients undergoing doxorubicin and trastuzumab therapy, 8 biomarkers were evaluated at baseline and every 3 months over a maximum follow-up of 15 months. These biomarkers, hypothesized to be mechanistically relevant to cardiotoxicity, included high-sensitivity cardiac troponin I (hs-cTnI), high-sensitivity C-reactive protein (hsCRP), N-terminal pro–B-type natriuretic peptide (NT-proBNP), growth differentiation factor 15 (GDF-15), myeloperoxidase (MPO), placental growth factor (PlGF), soluble fms-like tyrosine kinase receptor-1 (sFlt-1), and galectin 3 (gal-3). We determined if biomarker increases were associated with cardiotoxicity at the same visit and the subsequent visit over the entire course of therapy. Cardiotoxicity was defined by the Cardiac Review and Evaluation Criteria; alternative definitions were also considered. RESULTS Across the entire cohort, all biomarkers except NT-proBNP and gal-3 demonstrated increases by 3 months; these increases persisted for GDF-15, PlGF, and hs-cTnI at 15 months. Increases in MPO, PlGF, and GDF-15 were associated with cardiotoxicity at the same visit [MPO hazard ratio 1.38 (95% CI 1.10–1.71), P = 0.02; PlGF 3.78 (1.30–11.0), P = 0.047; GDF-15 1.71 (1.15–2.55), P = 0.01] and the subsequent visit. MPO was robust to alternative outcome definitions. CONCLUSIONS Increases in MPO are associated with cardiotoxicity over the entire course of doxorubicin and trastuzumab therapy. Assessment with PlGF and GDF-15 may also be of value. These findings motivate validation studies in additional cohorts." @default.
• W2111241903 created "2016-06-24" @default.
• W2111241903 creator A5001183727 @default.
• W2111241903 creator A5002939213 @default.
• W2111241903 creator A5015699633 @default.
• W2111241903 creator A5016136470 @default.
• W2111241903 creator A5024323248 @default.
• W2111241903 creator A5028866083 @default.
• W2111241903 creator A5039675046 @default.
• W2111241903 creator A5041625226 @default.
• W2111241903 creator A5043064522 @default.
• W2111241903 creator A5043760436 @default.
• W2111241903 creator A5049939460 @default.
• W2111241903 creator A5060660588 @default.
• W2111241903 creator A5062029203 @default.
• W2111241903 creator A5075241378 @default.
• W2111241903 creator A5078168657 @default.
• W2111241903 creator A5084265906 @default.
• W2111241903 creator A5091620472 @default.
• W2111241903 date "2015-09-01" @default.
• W2111241903 modified "2023-10-18" @default.
• W2111241903 title "Longitudinal Changes in Multiple Biomarkers Are Associated with Cardiotoxicity in Breast Cancer Patients Treated with Doxorubicin, Taxanes, and Trastuzumab" @default.
• W2111241903 cites W1969345980 @default.
• W2111241903 cites W1976801946 @default.
• W2111241903 cites W1977796000 @default.
• W2111241903 cites W1982181214 @default.
• W2111241903 cites W2005889240 @default.
• W2111241903 cites W2014166418 @default.
• W2111241903 cites W2021964897 @default.
• W2111241903 cites W2023272495 @default.
• W2111241903 cites W2029542561 @default.
• W2111241903 cites W2046927193 @default.
• W2111241903 cites W2076803848 @default.
• W2111241903 cites W2077157804 @default.
• W2111241903 cites W2077838200 @default.
• W2111241903 cites W2084304742 @default.
• W2111241903 cites W2089331342 @default.
• W2111241903 cites W2091699103 @default.
• W2111241903 cites W2093049418 @default.
• W2111241903 cites W2098268167 @default.
• W2111241903 cites W2101099004 @default.
• W2111241903 cites W2101253730 @default.
• W2111241903 cites W2104272500 @default.
• W2111241903 cites W2105436256 @default.
• W2111241903 cites W2112231610 @default.
• W2111241903 cites W2127284954 @default.
• W2111241903 cites W2136889865 @default.
• W2111241903 cites W2137159389 @default.
• W2111241903 cites W2142167347 @default.
• W2111241903 cites W2142877037 @default.
• W2111241903 cites W2147900049 @default.
• W2111241903 cites W2152573492 @default.
• W2111241903 cites W2153362990 @default.
• W2111241903 cites W2153821116 @default.
• W2111241903 cites W2154066911 @default.
• W2111241903 cites W2169835977 @default.
• W2111241903 cites W2253565143 @default.
• W2111241903 cites W4239462698 @default.
• W2111241903 cites W4247624557 @default.
• W2111241903 doi "https://doi.org/10.1373/clinchem.2015.241232" @default.
• W2111241903 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4667170" @default.
• W2111241903 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26220066" @default.
• W2111241903 hasPublicationYear "2015" @default.
• W2111241903 type Work @default.
• W2111241903 sameAs 2111241903 @default.
• W2111241903 citedByCount "118" @default.
• W2111241903 countsByYear W21112419032015 @default.
• W2111241903 countsByYear W21112419032016 @default.
• W2111241903 countsByYear W21112419032017 @default.
• W2111241903 countsByYear W21112419032018 @default.
• W2111241903 countsByYear W21112419032019 @default.
• W2111241903 countsByYear W21112419032020 @default.
• W2111241903 countsByYear W21112419032021 @default.
• W2111241903 countsByYear W21112419032022 @default.
• W2111241903 countsByYear W21112419032023 @default.
• W2111241903 crossrefType "journal-article" @default.
• W2111241903 hasAuthorship W2111241903A5001183727 @default.
• W2111241903 hasAuthorship W2111241903A5002939213 @default.
• W2111241903 hasAuthorship W2111241903A5015699633 @default.
• W2111241903 hasAuthorship W2111241903A5016136470 @default.
• W2111241903 hasAuthorship W2111241903A5024323248 @default.
• W2111241903 hasAuthorship W2111241903A5028866083 @default.
• W2111241903 hasAuthorship W2111241903A5039675046 @default.
• W2111241903 hasAuthorship W2111241903A5041625226 @default.
• W2111241903 hasAuthorship W2111241903A5043064522 @default.
• W2111241903 hasAuthorship W2111241903A5043760436 @default.
• W2111241903 hasAuthorship W2111241903A5049939460 @default.
• W2111241903 hasAuthorship W2111241903A5060660588 @default.
• W2111241903 hasAuthorship W2111241903A5062029203 @default.
• W2111241903 hasAuthorship W2111241903A5075241378 @default.
• W2111241903 hasAuthorship W2111241903A5078168657 @default.
• W2111241903 hasAuthorship W2111241903A5084265906 @default.
• W2111241903 hasAuthorship W2111241903A5091620472 @default.
• W2111241903 hasBestOaLocation W21112419031 @default.
• W2111241903 hasConcept C115725540 @default.
• W2111241903 hasConcept C121608353 @default.
• W2111241903 hasConcept C126322002 @default.
• W2111241903 hasConcept C136935669 @default.

• next